Form 4: Alumis Inc. Chief Medical Officer Jorn Drappa Reports Stock Option Transactions
SEC Form 4
Chief Medical Officer of Alumis Inc., Jorn Drappa, reports acquisition and disposal of stock options following a reclassification of Class A Common Stock.
Summary
- On July 1, 2024, Jorn Drappa, the Chief Medical Officer of Alumis Inc., filed a Form 4 detailing changes in beneficial ownership of securities.
- The report indicates transactions involving stock options, specifically the acquisition and disposal of options to buy Class A Common Stock, which were then reclassified into common stock.
- These transactions include the acquisition of options at various prices ($8.84, $10.20, $13.33, and $16) and the disposal of options at a price of $0.
- The reclassification was exempt under Rule 16b-7 and Rule 16b-3, where each share of Class A Common Stock was reclassified into one share of voting Common Stock.
- The vesting schedules for these options vary, with some vesting in installments over 36 or 48 months, and others contingent on the Issuer's satisfaction of certain performance criteria.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Positives
- The reporting of these transactions ensures transparency in insider trading activities.
- The reclassification of stock simplifies the capital structure of the company.
Industry Context
Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. This filing is typical for executives receiving and managing stock options as part of their compensation.
Comparison to Industry Standards
- Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with those of shareholders.
- Vesting schedules and performance-based vesting criteria are also standard practices to incentivize long-term performance.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders are informed about the transactions of a key executive, providing transparency.
- Employees may be indirectly affected by the vesting of options, as it can impact the company's share structure.
Key Dates
| Date | Description |
|---|---|
| 08/22/2023 | 25% of the shares underlying one option vested on this date. |
| 05/22/2024 | 25% of the shares underlying one option vested on this date. |
| 06/21/2024 | 25% of the shares underlying one option vest on this date. |
| 06/27/2024 | Date of earliest transaction reported. |
| 07/01/2024 | Date of the Form 4 filing and multiple transactions. |
| 08/22/2024 | 33% of the shares underlying one option vested on this date. |
| 10/09/2024 | 25% of the shares underlying one option vest on this date. |
| 03/29/2025 | 25% of the shares underlying one option vest on this date. |
| 06/06/2025 | 25% of the shares underlying one option vest on this date. |
| 05/06/2028 | First vesting date for one option, subject to performance criteria. |
| 05/06/2029 | Second vesting date for one option, subject to performance criteria. |
| 05/06/2030 | Third vesting date for one option, subject to performance criteria. |
| 08/29/2032 | Expiration date for some stock options. |
| 06/22/2033 | Expiration date for some stock options. |
| 10/08/2033 | Expiration date for some stock options. |
| 03/28/2034 | Expiration date for some stock options. |
| 05/05/2034 | Expiration date for some stock options. |
| 06/05/2034 | Expiration date for some stock options. |
| 06/26/2034 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.